Regeneron’s Eylea franchise boosted by pair of FDA approvals
Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
FDA unveils new pathway to usher bespoke therapies to market
The US Food and Drug Administration (FDA) has created a new pathway to bring personalised therapies to market that can…
-
FDA’s revolving door reveals Pazdur as new CDER head
The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking…
-
Europe looks east for clinical trial growth amid continent’s wider freeze
Amid the growing role of China in the clinical trial space and dominant investment role the US continues to play,…
-
Proactive strategy needed to ensure Project Optimus compliance
Sponsors should ensure dose optimisation is a part of early trial planning for oncology trials as the US Food and…
-
BIOSECURE returns to US pharma agenda with 2.0 update
After a year in the shadows, the controversial BIOSECURE Act could make a return following an endorsement of a revised…
-
China accounts for one-fifth of global drugs in development
China-based companies are responsible for 20% of drugs in development globally, reflecting the powerhouse role the country has embraced in…
-
Europe’s path to maintaining clinical trial hotbed of innovation
The European clinical trial landscape will take centre stage this October as leading voices from the biopharma and healthcare sectors convene…
-
Drugmakers point to US expansion plans amid Trump’s 100% drug tariff
The US will impose a 100% tariff on certain pharma products entering the country, the latest move by the Trump…
-
Bluebird bio flies to pastures new with Genetix rebranding
Bluebird bio has rebranded to Genetix Biotherapeutics, marking a new chapter for the company that was once a frontrunner in…